U.S. High Court To Hear Fosamax Preemption Case Jan. 7; Solicitor General Included
WASHINGTON, D.C. — Arguments about whether the Food and Drug Administration rejected a stronger warning about leg fractures on the label of the osteoporosis drug Fosamax will be heard by the...To view the full article, register now.
Already a subscriber? Click here to view full article